Lord Abbett & CO. LLC Acquires 119,182 Shares of IDEXX Laboratories, Inc. $IDXX

Lord Abbett & CO. LLC raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 175.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 187,009 shares of the company’s stock after buying an additional 119,182 shares during the period. Lord Abbett & CO. LLC’s holdings in IDEXX Laboratories were worth $126,517,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in the business. Wealthspire Advisors LLC lifted its stake in shares of IDEXX Laboratories by 12.7% in the fourth quarter. Wealthspire Advisors LLC now owns 4,861 shares of the company’s stock valued at $3,289,000 after buying an additional 546 shares in the last quarter. Quadrant Capital Group LLC lifted its stake in shares of IDEXX Laboratories by 1.0% in the fourth quarter. Quadrant Capital Group LLC now owns 2,046 shares of the company’s stock valued at $1,384,000 after buying an additional 20 shares in the last quarter. Livet Wealth LLC bought a new position in shares of IDEXX Laboratories in the fourth quarter valued at $206,000. Advisors Asset Management Inc. lifted its stake in shares of IDEXX Laboratories by 3.2% in the fourth quarter. Advisors Asset Management Inc. now owns 2,602 shares of the company’s stock valued at $1,760,000 after buying an additional 81 shares in the last quarter. Finally, CI Investments Inc. lifted its stake in shares of IDEXX Laboratories by 4.8% in the fourth quarter. CI Investments Inc. now owns 938 shares of the company’s stock valued at $635,000 after buying an additional 43 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $560.88 on Friday. IDEXX Laboratories, Inc. has a 52-week low of $506.91 and a 52-week high of $769.98. The company has a 50-day simple moving average of $563.06 and a 200 day simple moving average of $627.69. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The company has a market capitalization of $44.24 billion, a PE ratio of 41.30, a price-to-earnings-growth ratio of 3.05 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter last year, the company posted $2.91 earnings per share. The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, research analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. UBS Group lowered their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Stifel Nicolaus lowered their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Citigroup assumed coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price for the company. Finally, Wall Street Zen upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday. Seven equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.